Article
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Future oncology (London, England) - 1 Jan 2015
Foltran Luisa, De Maglio Giovanna, Pella Nicoletta, Ermacora Paola, Aprile Giuseppe, Masiero Elena, Giovannoni Mariella, Iaiza Emiliana, Cardellino Giovanni Gerardo, Lutrino Stefania Eufemia, Mazzer Micol, Giangreco Manuela, Pisa Federica Edith, Pizzolitto Stefano, Fasola Gianpiero
Abstract excerpt
AIM: To explore the prognostic value of extended mutational profiling for metastatic colorectal cancer (mCRC). MATERIALS & METHODS: We retrospectively reviewed survival results of 194 mCRC patients that were assigned to four molecular subgroups: BRAF mutated; KRAS mutated codons 12-13 only; any of KRAS codons 61-146, PIK3CA or NRAS mutations and all wild-type. Point mutations were investigated by pyrosequencing....
Topics
- Antineoplastic Combined Chemotherapy Protocols
- Class I Phosphatidylinositol 3-Kinases
- Colorectal Neoplasms
- Combined Modality Therapy
- DNA Mutational Analysis
- Female
- GTP Phosphohydrolases
- Humans